The company is building a development platform for exploring its proprietary substances with AT₂receptor agonistic properties.  The AT₂receptor is generally expressed abundantly in damaged tissue, e.g in kidneys, in the brain and in cardiovascular tissue. The clinical opportunities offered by AT₂stimulation are consequently spanning over numerous conditions and medical specialties. However, the strategic field for the company is the cardiovascular area where the development is furthered to the candidate drug stage and where company expertise is most prominent. This core field of operations is managed with internal resources and strategic R&D partners. 

For non-core indications and applications the company is open to partnering discussions with dedicated drug development partners.